TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7577202
Drug: Daunorubicin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin and cytarabine with granulocyte colony-stimulating factor (G-CSF) as supportive care
Study: 7577202
Drug: Daunorubicin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin and cytarabine without granulocyte colony-stimulating factor (G-CSF)
Study: 2013680
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with a maintenance dose of 1.94 micrograms of antigen E (Amb a I) for 8 months (total dose equivalent to 24 micrograms of antigen E)
Study: 6756509
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Tamoxifen + Immunotherapy
Study: 6756509
Drug: BCG Immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG Immunotherapy
Study: 30563829
Drug: Rapamycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin (3 mg orally daily)
Study: 29218705
Drug: Rapid AED
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid AED taper (30% to 50% dose reduction)
Study: 29218705
Drug: Slow AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow AED taper (15% to <30% dose reduction)
Study: 29218705
Drug: Rapid AED
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid AED taper
Study: 29218705
Drug: Slow AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow AED taper
Study: 24754230
Drug: Biological attributions
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological attributions
Study: 21997197
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - 2 injections of 1.25 mg with 6-week intervals
Study: 21997197
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab combined with triamcinolone (IVB/IVT) - 1.25 mg of IVB with 2 mg of IVT
Study: 21997197
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) - 2 mg of IVT
Study: 17665231
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (monotherapy)
Study: 17665231
Drug: Fluconazole (monotherapy)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (monotherapy)
Study: 17665231
Drug: Flucytosine (monotherapy)
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flucytosine (monotherapy)
Study: 17665231
Drug: Itraconazole (monotherapy)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole (monotherapy)
Study: 20139214
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics
Study: 20139214
Drug: Delayed antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotics
Study: 10463975
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin
Study: 2113036
Drug: Balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced amino acid solution (Study group)
Study: 28421677
Drug: MBSR (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBSR (8 weekly group sessions of MBSR)
Study: 25944411
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg administered intravenously) plus diet counselling
Study: 25944411
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of zoledronate (5 mg administered intravenously) plus diet counselling
Study: 25944411
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of zoledronate (5 mg administered intravenously) plus diet counselling
Study: 16484504
Drug: High trough
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High trough concentration (10‐15 ng/ml) group (HT group)
Study: 8633831
Drug: Once-daily aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily aminoglycoside dosing
Study: 1421050
Drug: Tegretol 200
Normalized name: Tegretol 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegretol 200 mg commercial tablets
Study: 1421050
Drug: carbamazepine OROS
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carbamazepine OROS controlled delivery tablets
Study: 27510380
Drug: DTaP‐IPV//Hib pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV//Hib pentavalent combination vaccine (Pentaxim™)
Study: 27510380
Drug: Separate DTaP‐IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate DTaP‐IPV and Hib vaccines
Study: 25061038
Drug: Placebo SWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SWD treatment
Study: 19451282
Drug: EDP-420 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-420 (400 mg/day loading dose, followed by 200 mg/day for 2 days)
Study: 19451282
Drug: EDP-420 capsule
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-420 capsule formulation
Study: 19451282
Drug: EDP-420 suspension
Normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP-420 suspension formulation
Study: 16505262
Drug: Cholecalciferol (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (700 IU) plus Calcium Citrate Malate (500 mg)
Study: 8000747
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture treatment at non-segmental distal points (homolateral leg)
Study: 3287976
Drug: Cefotetan 2
Normalized name: cefotetan 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 2 g once daily
Study: 3287976
Drug: Cefoxitin 1
Normalized name: cefoxitin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin 1 or 2 g three times daily
Study: 3927481
Drug: Bezafibrate 200
Normalized name: bezafibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 200 mg 3 times daily
Study: 22915294
Drug: Cowpea meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cowpea meal fortified with 10 mg Fe/meal as NaFeEDTA
Study: 19115654
Drug: Lignocaine alone
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine alone (9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Study: 19115654
Drug: Lignocaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine plus magnesium sulphate (6 ml of 25% magnesium sulphate plus 9 ml of 2% lignocaine diluted with normal saline to total volume of 36 ml)
Study: 3943744
Drug: Hyoscine‐N‐butylbromide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butylbromide (20 mg IV)
Study: 3943744
Drug: Hyoscine‐N‐butylbromide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butylbromide (40 mg IV)
Study: 24767296
Drug: Short-term thromboprophylaxis
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 7 days
Study: 24767296
Drug: Long-term thromboprophylaxis
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term thromboprophylaxis with oral rivaroxaban 10 mg once daily for 35 days
Study: 23248894
Drug: Novel multi-directional
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel multi-directional power toothbrush (Oral-B Professional Deep Sweep TRICLEAN 1000)
Study: 11978683
Drug: NVP DPP728
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP DPP728 at 100 mg t.i.d.
Study: 11978683
Drug: NVP DPP728
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP DPP728 at 150 mg b.i.d.
Study: 11978683
Drug: NVP DPP728
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP DPP728 (combined active treatment groups)
Study: 11978683
Drug: NVP DPP728
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP DPP728 at 100 mg t.i.d. and 150 mg b.i.d.
Study: 2871819
Drug: Diazepam (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (4.4 to 140 micrograms/kg, cumulative dose)
Study: 30043330
Drug: G‐CSF +
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF + plerixafor (GP arm)
Study: 30043330
Drug: G‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF alone (G arm)
Study: 29145540
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg daily)
Study: 27764050
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg daily)
Study: 24632673
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human activated protein C (rh-APC) 24 mcg/kg/h for 4 days
Study: 22572649
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg in 20 mL 0.9% saline)
Study: 22572649
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL 0.9% saline)
Study: 8540714
Drug: Ceftazidime 25
Normalized name: ceftazidime 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 25 mg/kg once daily
Study: 8540714
Drug: Ceftazidime 25
Normalized name: ceftazidime 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 25 mg/kg twice daily
Study: 1786500
Drug: Pramiracetam sulphate
Normalized name: aniracetam
DrugBank: Pramiracetam (DB13247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramiracetam sulphate 400 mg TID
Study: 13679688
Drug: Control (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (medical treatment)
Study: 19508900
Drug: Celecoxib (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (specific dosage and duration not mentioned)
Study: 17348993
Drug: Comparative water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative water spray
Study: 2450441
Drug: Atracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.1 mg kg‐1
Study: 2450441
Drug: Pancuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.6 mg kg‐1
Study: 29694816
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (approximately 20 mg per kilogram of body weight)
Study: 18706905
Drug: 100 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/day transdermal estradiol
Study: 3882681
Drug: Fluoxetine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 30 mg
Study: 8199601
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg
Study: 1359846
Drug: 500-mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg daily dose of zidovudine
Study: 1359846
Drug: 1500-mg daily
Normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500-mg daily dose of zidovudine
Study: 1359846
Drug: Zidovudine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (both doses)
Study: 3925770
Drug: Ciba transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciba transdermal nitroglycerin placebo patch
Study: 3925770
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches (Ciba, Key, Searle)
Study: 22785499
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy group (n = 7; CABG and injection of bone marrow mononuclear cells (BMNCs) within MI areas)
Study: 22785499
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy group (n = 7)
Study: 20159906
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 8 weeks
Study: 12749424
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) injection of 10,000 IU of hCG
Study: 12749424
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) injection of 10,000 IU of hCG
Study: 8706443
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Study: 8706443
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Study: 6810736
Drug: Merck 20‐micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck 20‐micrograms hepatitis B virus (HBV) vaccine
Study: 27071072
Drug: Hotspot-targeted interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hotspot-targeted interventions (larviciding, distribution of long-lasting insecticide-treated nets, indoor residual spraying, focal mass drug administration)
Study: 22876835
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 17.5 μg/h
Study: 22876835
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 35 μg/h
Study: 22876835
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 52.5 μg/h
Study: 22876835
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS)
Study: 21133003
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection and pneumatic dilation (BT+PD)
Study: 17715139
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg kg(‐1)
Study: 17715139
Drug: Metoclopramide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.5 mg kg(‐1)
Study: 15253175
Drug: Support received
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support received during diagnosis and treatment
Study: 11684527
Drug: CP‐DC diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP‐DC diet (22 g cocoa powder and 16 g dark chocolate)
Study: 8070499
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup
Study: 7926968
Drug: Phorbol myristate
Normalized name: Phorbol myristate acetate
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phorbol myristate acetate (PMA) treatment
Study: 2478048
Drug: Midazolam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (5 mg im)
Study: 2478048
Drug: Oxymorphone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone (1 mg iv)
Study: 28059869
Drug: Longitudinal supra‐inguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal supra‐inguinal fascia iliaca compartment block with 40‐mL ropivacaine 0.5%
Study: 23689115
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) plus intravitreal bevacizumab (IVB) injections
Study: 15134316
Drug: 15‐min single‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐min single‐dose brief intervention
Study: 11375808
Drug: Milrinone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (50 micro/kg) administered through the bypass pump 10 min before aortic cross-clamping
Study: 9404430
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy (specifics not provided)
Study: 8495453
Drug: Diclofenac-K 50
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac-K 50 mg
Study: 8495453
Drug: Diclofenac-K 100
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac-K 100 mg
Study: 30844477
Drug: Ginger supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger supplementation (1500 mg daily for 12 weeks)
Study: 11736876
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (4 mg kg(‐1))
Study: 11736876
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (4 mg kg(‐1))
Study: 11736876
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (first day of treatment)
Study: 11736876
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (second day of treatment)
Study: 11736876
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo parasite clearance and time above the in vitro IC90 for both drugs
Study: 28598116
Drug: LE+CC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LE+CC
Study: 28598116
Drug: CC+HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC+HMG
Study: 28598116
Drug: LE+CC+HMG
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LE+CC+HMG
Study: 11464141
Drug: Protease Inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitor (Group B)
Study: 9552778
Drug: bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine + both (i.t. 10 mg bupivacaine + 50 microg neostigmine + 150 microg clonidine)
Study: 9552778
Drug: bupivacaine (i.t.
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine (i.t. 10 mg bupivacaine)
Study: 9552778
Drug: bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine + neostigmine (i.t. 10 mg bupivacaine + 50 microg neostigmine)
Study: 9552778
Drug: bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine + clonidine (i.t. 10 mg bupivacaine + 150 microg clonidine)
Study: 7868704
Drug: Matched controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched controls from the Child Health Supplement of the National Health Interview Survey (CHS88)
Study: 3421598
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention treatment
Study: 7263877
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (control)
Study: 28851065
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 270 μg kg‐1 rFVIIa
Study: 28851065
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 3×90 μg kg‐1 rFVIIa
Study: 25285748
Drug: Cardiac contractility
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT)
Study: 25285748
Drug: Cardiac contractility
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT) in patients with EFs ranging from 25% to 45%
Study: 22949122
Drug: Dexamethasone +
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone + Ibuprofen
Study: 21448073
Drug: Dexketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen (50 mg) intravenously
Study: 21448073
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of 0.9% NaCL) intravenously
Study: 12830447
Drug: Home hemodialysis
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home hemodialysis (HD) with the Fresenius 2008H machine and Service Deionization Tank (SDI) water treatment system
Study: 10854552
Drug: Cisplatin-based cyclic
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy (BOAI)
Study: 8464671
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (20 mg) aerosolized every 6 hours starting on the first day of intubation
Study: 31268250
Drug: GSK256073 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 5 mg/day
Study: 31268250
Drug: GSK256073 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 50 mg/day
Study: 31268250
Drug: GSK256073 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256073 150 mg/day
Study: 23091096
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment (chemotherapy every 14 days)
Study: 23091096
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (chemotherapy every 21 days)
Study: 17997459
Drug: Epirubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (50 mg instillation)
Study: 10036609
Drug: 0.62 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.62 g/kg alcohol
Study: 19278796
Drug: 0.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/kg alcohol
Study: 24519012
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g/kg)